Great Point Partners’s Tenax Therapeutics TENX Stock Holding History

Great Point Partners’s Portfolio TENX Stock Details TENX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-327,307	Closed	-$5.23M	–	52
2026 Q1	$5.23M	Buy	+327,307	New	+$4.43M	1.2%	31
2017 Q1	–	Sell	-35	Closed	-$2.16M	–	44
2016 Q4	$2.16M	Hold	35	–	–	0.44%	30
2016 Q3	$2.57M	Hold	35	–	–	0.66%	24
2016 Q2	$2.84M	Hold	35	–	–	0.81%	26
2016 Q1	$2.27M	Hold	35	–	–	0.82%	26
2015 Q4	$3.64M	Hold	35	–	–	1.53%	19
2015 Q3	$3.33M	Hold	35	–	–	1.32%	25
2015 Q2	$4.09M	Hold	35	–	–	1.59%	23
2015 Q1	$3.61M	Hold	35	–	–	1.59%	19
2014 Q4	$4.26M	Hold	35	–	–	2.05%	15
2014 Q3	$4.38M	Sell	35 -31	-47%	-$3.98M	1.88%	23
2014 Q2	$8.63M	Buy	66 +3	+5%	+$463K	3.84%	11
2014 Q1	$11.1M	Buy	+63	New	+$12.5M	5.8%	6

Other funds holding TENX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Great Point Partners's TENX Position: Q2 2026 in Review

Great Point Partners sold out of Tenax Therapeutics (TENX) in Q2 2026, closing a stake of 327,307 shares — an estimated $5.23M sold.

Great Point Partners first reported a position in TENX in Q1 2014 and held it in 13 quarters. The position peaked at $11.1M in Q1 2014. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

Great Point Partners reported no remaining Tenax Therapeutics position as of Q2 2026 after selling out during the quarter.
Great Point Partners sold 327,307 Tenax Therapeutics shares in Q2 2026, an estimated $5.23M.
Great Point Partners first reported a position in Tenax Therapeutics in Q1 2014 and held it in 13 quarters.
Great Point Partners's Tenax Therapeutics position peaked at $11.1M in Q1 2014.
111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.